The DOI matches its Crossref record; 227 of the 227 references it cites were found in a registry or an index.
Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities
Open accessAbstract
An incomplete view of the mechanisms that drive metastasis, the primary cause of cancer-related death, has been a major barrier to development of effective therapeutics and prognostic diagnostics. Increasing evidence indicates that the interplay between microenvironment, genetic lesions, and cellular plasticity drives the metastatic cascade and resistance to therapies. Here, using melanoma as a model, we outline the diversity and trajectories of cell states during metastatic dissemination and therapy exposure, and highlight how understanding the magnitude and dynamics of nongenetic reprogramming in space and time at single-cell resolution can be exploited to develop therapeutic strategies that capitalize on nongenetic tumor evolution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 2×
“…or so major advanc- es in melanoma therapy, from targeting oncogenic BRAF and MEK through to the breakthroughs in immunotherapies (Hodi et al. 2010; Chapman et al. 2011; Long et al. 2014; Robert et al. 2015a,b; Wolchok et al. 2017; Ascierto et al. 2019; Ribas et al. 2019) have led to important…”
BackgroundNowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 1×
“…BRAF and MEK through to the breakthroughs in immunotherapies (Hodi et al. 2010; Chapman et al. 2011; Long et al. 2014; Robert et al. 2015a,b; Wolchok et al. 2017; Ascierto et al. 2019; Ribas et al. 2019) have led to important lessons for cancer therapy in general and highlighted the many…”
BackgroundDissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
An Integrated Stress Response Regulates Amino Acid Metabolism and Resistance to Oxidative Stress
Harding, H. P., Zhang, Y., Zeng, H., Novoa, I., Lu, P. D., Calfon, M., Sadri, N., Yun, C., Popko, B., Paules, R., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00105-9 · Cited by 3,323
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302 · cited 1×
“Chemotherapy induces a switch in various epithelial cancers (carcinomas) (Dallas et al. 2009; Polyak and Weinberg 2009; Singh and Settleman 2010) such as colon (Dallas et al. 2009) and gastric (Xue et al. 2012), known as an epithelial-to-mesenchymal transition (EMT), an event associated with…”
BackgroundRegulated Translation Initiation Controls Stress-Induced Gene Expression in Mammalian Cells
Harding, H. P., Novoa, I., Zhang, Y., Zeng, H., Wek, R., Schapira, M., & Ron, D. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00108-8 · Cited by 3,276
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H. M., Jones, D. L., Visvader, J., Weissman, I. L., & Wahl, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3126 · Cited by 3,051
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., Richman, A. R., Silverbush, D., Shaw, M. L., Hebert, C. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.024 · Cited by 2,873
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,389
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry
Maniotis, A. J., Folberg, R., Hess, A., Seftor, E. A., Gardner, L. M. G., Pe'er, J., Trent, J. M., Meltzer, P. S., & Hendrix, M. J. C. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65173-5 · Cited by 2,043
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Efficient tumour formation by single human melanoma cells
Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. J. (2008) · Nature · doi:10.1038/nature07567 · Cited by 1,796
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 2×
“2015a), and have been implicated in promoting resistance to BRAF inhibitor therapy by secretion of hepatocyte growth factor (HGF) (Straussman et al. 2012; Almeida et al. 2019).”
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737
Phenotype molding of stromal cells in the lung tumor microenvironment
Lambrechts, D., Wauters, E., Boeckx, B., Aibar, S., Nittner, D., Burton, O., Bassez, A., Decaluwé, H., Pircher, A., Van den Eynde, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0096-5 · Cited by 1,648
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Van Raamsdonk, C. D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’Brien, J. M., Simpson, E. M., Barsh, G. S., & Bastian, B. C. (2009) · Nature · doi:10.1038/nature07586 · Cited by 1,623
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Identification of the tumour transition states occurring during EMT
Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Van Keymeulen, A., Brown, D., Moers, V., Lemaire, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0040-3 · Cited by 1,495
Self-citationMutations in GNA11 in Uveal Melanoma
Van Raamsdonk, C. D., Griewank, K. G., Crosby, M. B., Garrido, M. C., Vemula, S., Wiesner, T., Obenauf, A. C., Wackernagel, W., Green, G., Bouvier, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000584 · Cited by 1,476
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475
Targeting metastasis-initiating cells through the fatty acid receptor CD36
Pascual, G., Avgustinova, A., Mejetta, S., Martín, M., Castellanos, A., Attolini, C. S.-O., Berenguer, A., Prats, N., Toll, A., Hueto, J. A., et al. (2017) · Nature · doi:10.1038/nature20791 · Cited by 1,437
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
Identification of cells initiating human melanomas
Schatton, T., Murphy, G. F., Frank, N. Y., Yamaura, K., Waaga-Gasser, A. M., Gasser, M., Zhan, Q., Jordan, S., Duncan, L. M., Weishaupt, C., et al. (2008) · Nature · doi:10.1038/nature06489 · Cited by 1,415
Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data
Racle, J., de Jonge, K., Baumgaertner, P., Speiser, D. E., & Gfeller, D. (2017) · eLife · doi:10.7554/elife.26476 · Cited by 1,384
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · cited 1×
“Indeed, the durable response rate to any approved therapy still remains relatively low and the vast majority of patients who initially respond to treatment later develop resistance (Luke et al. 2017; Jenkins et al. 2018).”
BackgroundMigrating cancer stem cells — an integrated concept of malignant tumour progression
Brabletz, T., Jung, A., Spaderna, S., Hlubek, F., & Kirchner, T. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1694 · Cited by 1,352
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
The Response of CD24 −/low /CD44 + Breast Cancer–Initiating Cells to Radiation
Phillips, T. M., McBride, W. H., & Pajonk, F. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj495 · Cited by 1,309
A tumorigenic subpopulation with stem cell properties in melanomas
Fang, D., Nguyen, T. K., Leishear, K., Finko, R., Kulp, A. N., Hotz, S., Van Belle, P. A., Xu, X., Elder, D. E., & Herlyn, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1343 · Cited by 1,280
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218 · cited 6×
“…more recent evidence indicated that the dedifferentiated, invasive (MITFLow) phenotype is intrinsically resistant to MAPK pathway inhibitors and immunotherapies (Roesch et al. 2010; Kemper et al. 2014; Hugo et al. 2015, 2016; Verfaillie et al. 2015; Titz et al. 2016; Shaffer et al. 2017).”
BackgroundResultInfluentialRoesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., & Herlyn, M. (2010) · Cell · doi:10.1016/j.cell.2010.04.020 · Cited by 1,158
The perivascular niche regulates breast tumour dormancy
Ghajar, C. M., Peinado, H., Mori, H., Matei, I. R., Evason, K. J., Brazier, H., Almeida, D., Koller, A., Hajjar, K. A., Stainier, D. Y. R., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2767 · Cited by 1,148 · cited 1×
“It has been proposed that some melanoma cells may actually reside in the vasculature of the lungs (Ghajar et al. 2013), and be maintained in a dormant state for a prolonged period of time.”
BackgroundNormal and neoplastic nonstem cells can spontaneously convert to a stem-like state
Chaffer, C. L., Brueckmann, I., Scheel, C., Kaestli, A. J., Wiggins, P. A., Rodrigues, L. O., Brooks, M., Reinhardt, F., Su, Y., Polyak, K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102454108 · Cited by 1,147
Mechanisms of disseminated cancer cell dormancy: an awakening field
Sosa, M. S., Bragado, P., & Aguirre-Ghiso, J. A. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3793 · Cited by 1,126
Hodgkinson, C. A., Moore, K. J., Nakayama, A., Steingrímsson, E., Copeland, N. G., Jenkins, N. A., & Arnheiter, H. (1993) · Cell · doi:10.1016/0092-8674(93)90429-t · Cited by 1,094
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution
McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077
Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., & Yang, J. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.022 · Cited by 1,071
Sticking together: building a biofilm the Bacillus subtilis way
Vlamakis, H., Chai, Y., Beauregard, P., Losick, R., & Kolter, R. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2960 · Cited by 1,036
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988
Cancer stem cells: mirage or reality?
Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009) · Nature Medicine · doi:10.1038/nm0909-1010 · Cited by 979
Ocaña, O. H., Córcoles, R., Fabra, Á., Moreno-Bueno, G., Acloque, H., Vega, S., Barrallo-Gimeno, A., Cano, A., & Nieto, M. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.012 · Cited by 973
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science · doi:10.1126/science.1256930 · Cited by 965
Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.017 · Cited by 938
Unravelling cancer stem cell potential
Beck, B., & Blanpain, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3597 · Cited by 905
Shain, A. H., & Bastian, B. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.37 · Cited by 896
Cancer Stem Cells: Basic Concepts and Therapeutic Implications
Nassar, D., & Blanpain, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044438 · Cited by 869
EMT, cell plasticity and metastasis
Chaffer, C. L., San Juan, B. P., Lim, E., & Weinberg, R. A. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9648-7 · Cited by 861
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818 · cited 3×
“Consequently, MITF melanoma subpopulations, which, as described above, can be induced upon exposure to MAPK therapeutics, express high levels of PGC1α and are addicted to oxidative phosphorylation (Haq et al. 2013).”
BackgroundMetastasis genes: A progression puzzle
Bernards, R., & Weinberg, R. A. (2002) · Nature · doi:10.1038/418823a · Cited by 798
DNA repair, genome stability and cancer: a historical perspective
Jeggo, P. A., Pearl, L. H., & Carr, A. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.4 · Cited by 774
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771
Self-citationPan-cancer analysis of the extent and consequences of intratumor heterogeneity
Andor, N., Graham, T. A., Jansen, M., Xia, L. C., Aktipis, C. A., Petritsch, C., Ji, H. P., & Maley, C. C. (2016) · Nature Medicine · doi:10.1038/nm.3984 · Cited by 768
McGill, G. G., Horstmann, M., Widlund, H. R., Du, J., Motyckova, G., Nishimura, E. K., Lin, Y.-L., Ramaswamy, S., Avery, W., Ding, H.-F., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00762-6 · Cited by 760
Onken, M. D., Worley, L. A., Ehlers, J. P., & Harbour, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1750 · Cited by 750
In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
Hoek, K. S., Eichhoff, O. M., Schlegel, N. C., Döbbeling, U., Kobert, N., Schaerer, L., Hemmi, S., & Dummer, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2491 · Cited by 743
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271
Boiko, A. D., Razorenova, O. V., van de Rijn, M., Swetter, S. M., Johnson, D. L., Ly, D. P., Butler, P. D., Yang, G. P., Joshua, B., Kaplan, M. J., et al. (2010) · Nature · doi:10.1038/nature09161 · Cited by 720
Vazquez, F., Lim, J.-H., Chim, H., Bhalla, K., Girnun, G., Pierce, K., Clish, C. B., Granter, S. R., Widlund, H. R., Spiegelman, B. M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.020 · Cited by 715
Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
Seguin, L., Desgrosellier, J. S., Weis, S. M., & Cheresh, D. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.12.006 · Cited by 685
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674 · cited 1×
“…nature of genetic mutations, such as point mutations that directly alter the target domain of protein kinases where selective inhibitor drugs bind (Knight et al. 2010; Sabnis and Bivona 2019) illustrates the power of “Darwinian” selection and highlight the need to improve effectiveness of…”
BackgroundRoesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.003 · Cited by 670 · cited 2×
“As a consequence, targeting mitochondrial respiration blocked the emergence of the slow cycling population and overcame their nongenetic intrinsic drug resistance (Roesch et al. 2013).”
BackgroundResolving genetic heterogeneity in cancer
Turajlic, S., Sottoriva, A., Graham, T., & Swanton, C. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0114-6 · Cited by 653
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639
Self-citationMelanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
Landsberg, J., Kohlmeyer, J., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M., et al. (2012) · Nature · doi:10.1038/nature11538 · Cited by 632
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A., Larue, L., & Goding, C. R. (2006) · Genes & Development · doi:10.1101/gad.406406 · Cited by 608
Self-citationUnderstanding and targeting cancer stem cells: therapeutic implications and challenges
Chen, K., Huang, Y.-H., & Chen, J.-L. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.27 · Cited by 608
WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells
Woodward, W. A., Chen, M. S., Behbod, F., Alfaro, M. P., Buchholz, T. A., & Rosen, J. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606599104 · Cited by 603
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 600
Quintana, E., Shackleton, M., Foster, H. R., Fullen, D. R., Sabel, M. S., Johnson, T. M., & Morrison, S. J. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.012 · Cited by 599
Mechanisms Governing Metastatic Dormancy and Reactivation
Giancotti, F. G. (2013) · Cell · doi:10.1016/j.cell.2013.10.029 · Cited by 586
Dallas, N. A., Xia, L., Fan, F., Gray, M. J., Gaur, P., van Buren, G., Samuel, S., Kim, M. P., Lim, S. J., & Ellis, L. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2023 · Cited by 572
Vanharanta, S., & Massagué, J. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.007 · Cited by 563
Hoek, K. S., Schlegel, N. C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., Weber, B. L., Nathanson, K. L., Phillips, D. J., Herlyn, M., et al. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00322.x · Cited by 555
Translational Implications of Tumor Heterogeneity
Jamal-Hanjani, M., Quezada, S. A., Larkin, J., & Swanton, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1429 · Cited by 549
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3122 · Cited by 547
Control of cell fate by the formation of an architecturally complex bacterial community
Vlamakis, H., Aguilar, C., Losick, R., & Kolter, R. (2008) · Genes & Development · doi:10.1101/gad.1645008 · Cited by 545
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
Konieczkowski, D. J., Johannessen, C. M., Abudayyeh, O., Kim, J. W., Cooper, Z. A., Piris, A., Frederick, D. T., Barzily-Rokni, M., Straussman, R., Haq, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0424 · Cited by 535
Wu, M., Hemesath, T. J., Takemoto, C. M., Horstmann, M. A., Wells, A. G., Price, E. R., Fisher, D. Z., & Fisher, D. E. (2000) · Genes & Development · doi:10.1101/gad.14.3.301 · Cited by 527
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
Bertolotto, C., Lesueur, F., Giuliano, S., Strub, T., de Lichy, M., Bille, K., Dessen, P., d’Hayer, B., Mohamdi, H., Remenieras, A., et al. (2011) · Nature · doi:10.1038/nature10539 · Cited by 526
Eyles, J., Puaux, A.-L., Wang, X., Toh, B., Prakash, C., Hong, M., Tan, T. G., Zheng, L., Ong, L. C., Jin, Y., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42002 · Cited by 506
Cancer stem cells versus phenotype‐switching in melanoma
Hoek, K. S., & Goding, C. R. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00757.x · Cited by 506
Self-citationDecoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms7683 · Cited by 489
Self-citationFeedback Loops Shape Cellular Signals in Space and Time
Brandman, O., & Meyer, T. (2008) · Science · doi:10.1126/science.1160617 · Cited by 471
Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage
Goding, C. R. (2000) · Genes & Development · doi:10.1101/gad.14.14.1712 · Cited by 471
Self-citationInteraction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome
Bondurand, N. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.13.1907 · Cited by 467
Goding, C. R., & Arnheiter, H. (2019) · Genes & Development · doi:10.1101/gad.324657.119 · Cited by 430
Self-citationHuang, R. Y.-J., Wong, M. K., Tan, T. Z., Kuay, K. T., Ng, A. H. C., Chung, V. Y., Chu, Y.-S., Matsumura, N., Lai, H.-C., Lee, Y. F., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.442 · Cited by 427
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Gerlinger, M., & Swanton, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605912 · Cited by 421
Mroz, E. A., & Rocco, J. W. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2012.09.007 · Cited by 417
Quantifying tumor-infiltrating immune cells from transcriptomics data
Finotello, F., & Trajanoski, Z. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2150-z · Cited by 407
Radiation‐Induced Reprogramming of Breast Cancer Cells
Lagadec, C., Vlashi, E., Della Donna, L., Dekmezian, C., & Pajonk, F. (2012) · STEM CELLS · doi:10.1002/stem.1058 · Cited by 401
Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
Schwarz, R. F., Ng, C. K. Y., Cooke, S. L., Newman, S., Temple, J., Piskorz, A. M., Gale, D., Sayal, K., Murtaza, M., Baldwin, P. J., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001789 · Cited by 400
Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression
Carreira, S., Goodall, J., Aksan, I., La Rocca, S. A., Galibert, M.-D., Denat, L., Larue, L., & Goding, C. R. (2005) · Nature · doi:10.1038/nature03269 · Cited by 395
Self-citationPotterf, S. B., Furumura, M., Dunn, K. J., Arnheiter, H., & Pavan, W. J. (2000) · Human Genetics · doi:10.1007/s004390000328 · Cited by 379
Combinatorial function of transcription factors and cofactors
Reiter, F., Wienerroither, S., & Stark, A. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.12.007 · Cited by 364
Cheli, Y., Ohanna, M., Ballotti, R., & Bertolotto, C. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00653.x · Cited by 363
Metabolic Reprogramming of Cancer-Associated Fibroblasts by IDH3α Downregulation
Zhang, D., Wang, Y., Shi, Z., Liu, J., Sun, P., Hou, X., Zhang, J., Zhao, S., Zhou, B. P., & Mi, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.006 · Cited by 333
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0448-9 · Cited by 324
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Ribas, A., Lawrence, D., Atkinson, V., Agarwal, S., Miller, W. H., Carlino, M. S., Fisher, R., Long, G. V., Hodi, F. S., Tsoi, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0476-5 · Cited by 323
Feng, Y.-X., Sokol, E. S., Del Vecchio, C. A., Sanduja, S., Claessen, J. H. L., Proia, T. A., Jin, D. X., Reinhardt, F., Ploegh, H. L., Wang, Q., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0945 · Cited by 319
Non-Darwinian dynamics in therapy-induced cancer drug resistance
Pisco, A. O., Brock, A., Zhou, J., Moor, A., Mojtahedi, M., Jackson, D., & Huang, S. (2013) · Nature Communications · doi:10.1038/ncomms3467 · Cited by 297
Widlund, H. R., Horstmann, M. A., Price, E. R., Cui, J., Lessnick, S. L., Wu, M., He, X., & Fisher, D. E. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200202049 · Cited by 291
Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis
Lehuédé, C., Dupuy, F., Rabinovitch, R., Jones, R. G., & Siegel, P. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0266 · Cited by 289
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
Zhang, G., Frederick, D. T., Wu, L., Wei, Z., Krepler, C., Srinivasan, S., Chae, Y. C., Xu, X., Choi, H., Dimwamwa, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82661 · Cited by 286
Pisco, A. O., & Huang, S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.146 · Cited by 283
Tumor Cell Vasculogenic Mimicry
Seftor, R. E. B., Hess, A. R., Seftor, E. A., Kirschmann, D. A., Hardy, K. M., Margaryan, N. V., & Hendrix, M. J. C. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.07.013 · Cited by 282
Pearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N. R., Geh, C., Rooney, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1246 · Cited by 276
Strub, T., Giuliano, S., Ye, T., Bonet, C., Keime, C., Kobi, D., Le Gras, S., Cormont, M., Ballotti, R., Bertolotto, C., et al. (2011) · Oncogene · doi:10.1038/onc.2010.612 · Cited by 269 · cited 2×
“2010), and DNA damage repair and chromosome stability (Giuliano et al. 2010; Strub et al. 2011).”
BackgroundLoercher, A. E., Tank, E. M. H., Delston, R. B., & Harbour, J. W. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200410115 · Cited by 266
The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer
Salgia, R., & Kulkarni, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.01.001 · Cited by 264
Smith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., Lee, J. L., Girotti, M. R., Marais, R., Levesque, M. P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.003 · Cited by 246
Regulation of transcription factor activity by interconnected post-translational modifications
Filtz, T. M., Vogel, W. K., & Leid, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.005 · Cited by 242
Xu, W., Gong, L., Haddad, M. M., Bischof, O., Campisi, J., Yeh, E. T. H., & Medrano, E. E. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4803 · Cited by 241
Falletta, P., Sanchez-del-Campo, L., Chauhan, J., Effern, M., Kenyon, A., Kershaw, C. J., Siddaway, R., Lisle, R., Freter, R., Daniels, M. J., et al. (2017) · Genes & Development · doi:10.1101/gad.290940.116 · Cited by 239
Self-citationDeconstructing Olfactory Stem Cell Trajectories at Single-Cell Resolution
Fletcher, R. B., Das, D., Gadye, L., Street, K. N., Baudhuin, A., Wagner, A., Cole, M. B., Flores, Q., Choi, Y. G., Yosef, N., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.04.003 · Cited by 238
Fan, J., Lee, H.-O., Lee, S., Ryu, D.-E., Lee, S., Xue, C., Kim, S. J., Kim, K., Barkas, N., Park, P. J., et al. (2018) · Genome Research · doi:10.1101/gr.228080.117 · Cited by 237
Fallahi‐Sichani, M., Becker, V., Izar, B., Baker, G. J., Lin, J., Boswell, S. A., Shah, P., Rotem, A., Garraway, L. A., & Sorger, P. K. (2017) · Molecular Systems Biology · doi:10.15252/msb.20166796 · Cited by 235
Cheli, Y., Guiliano, S., Botton, T., Rocchi, S., Hofman, V, Hofman, P., Bahadoran, P., Bertolotto, C., & Ballotti, R. (2011) · Oncogene · doi:10.1038/onc.2010.598 · Cited by 231
Boshuizen, J., Koopman, L. A., Krijgsman, O., Shahrabi, A., van den Heuvel, E. G., Ligtenberg, M. A., Vredevoogd, D. W., Kemper, K., Kuilman, T., Song, J.-Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4472 · Cited by 229
MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells
Ploper, D., Taelman, V. F., Robert, L., Perez, B. S., Titz, B., Chen, H.-W., Graeber, T. G., von Euw, E., Ribas, A., & De Robertis, E. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424576112 · Cited by 228 · cited 4×
“2011, 2012), lysosome biogenesis (Ploper et al. 2015; Zhang et al. 2015b) and autophagy (Möller et al.”
BackgroundInfluentialSu, Y., Wei, W., Robert, L., Xue, M., Tsoi, J., Garcia-Diaz, A., Homet Moreno, B., Kim, J., Ng, R. H., Lee, J. W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712064115 · Cited by 228
Riesenberg, S., Groetchen, A., Siddaway, R., Bald, T., Reinhardt, J., Smorra, D., Kohlmeyer, J., Renn, M., Phung, B., Aymans, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms9755 · Cited by 227
Self-citationNagelkerke, A., Bussink, J., Mujcic, H., Wouters, B. G., Lehmann, S., Sweep, F. C., & Span, P. N. (2013) · Breast Cancer Research · doi:10.1186/bcr3373 · Cited by 225
A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data
Li, Y., Kang, K., Krahn, J. M., Croutwater, N., Lee, K., Umbach, D. M., & Li, L. (2017) · BMC Genomics · doi:10.1186/s12864-017-3906-0 · Cited by 223
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216
Undercover: gene control by metabolites and metabolic enzymes
van der Knaap, J. A., & Verrijzer, C. P. (2016) · Genes & Development · doi:10.1101/gad.289140.116 · Cited by 214
Abubaker, K., Latifi, A., Luwor, R., Nazaretian, S., Zhu, H., Quinn, M. A., Thompson, E. W., Findlay, J. K., & Ahmed, N. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-24 · Cited by 213
Goodall, J., Carreira, S., Denat, L., Kobi, D., Davidson, I., Nuciforo, P., Sturm, R. A., Larue, L., & Goding, C. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1053 · Cited by 208
Self-citationKondo, A., Yamamoto, S., Nakaki, R., Shimamura, T., Hamakubo, T., Sakai, J., Kodama, T., Yoshida, T., Aburatani, H., & Osawa, T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.006 · Cited by 206
Pinner, S., Jordan, P., Sharrock, K., Bazley, L., Collinson, L., Marais, R., Bonvin, E., Goding, C., & Sahai, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0781 · Cited by 202
Self-citationLaurette, P., Strub, T., Koludrovic, D., Keime, C., Le Gras, S., Seberg, H., Van Otterloo, E., Imrichova, H., Siddaway, R., Aerts, S., et al. (2015) · eLife · doi:10.7554/elife.06857 · Cited by 199
How to make a melanoma: what do we know of the primary clonal events?
Bennett, D. C. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2007.00433.x · Cited by 198
Schepsky, A., Bruser, K., Gunnarsson, G. J., Goodall, J., Hallsson, J. H., Goding, C. R., Steingrimsson, E., & Hecht, A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02299-05 · Cited by 197
Self-citationDemonstration of multiple phenotypic diversity in a murine melanoma of recent origin.
Fidler, I. J., Gruys, E., Cifone, M. A., Barnes, Z., & Bucana, C. D. (1981) · PubMed · Cited by 194
Lineage-specific Signaling in Melanocytes
Price, E. R., Ding, H.-F., Badalian, T., Bhattacharya, S., Takemoto, C., Yao, T.-P., Hemesath, T. J., & Fisher, D. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.17983 · Cited by 191
Sabnis, A. J., & Bivona, T. G. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.009 · Cited by 189
Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells
Cheli, Y., Giuliano, S., Fenouille, N., Allegra, M., Hofman, V, Hofman, P., Bahadoran, P., Lacour, J.-P., Tartare-Deckert, S., Bertolotto, C., et al. (2012) · Oncogene · doi:10.1038/onc.2011.425 · Cited by 185
Multiple steps in the regulation of transcription-factor level and activity
CALKHOVEN, C. F., & AB, G. (1996) · Biochemical Journal · doi:10.1042/bj3170329 · Cited by 183
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
Mehta, A., Kim, Y. J., Robert, L., Tsoi, J., Comin-Anduix, B., Berent-Maoz, B., Cochran, A. J., Economou, J. S., Tumeh, P. C., Puig-Saus, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1178 · Cited by 183
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
Bell, C. C., Fennell, K. A., Chan, Y.-C., Rambow, F., Yeung, M. M., Vassiliadis, D., Lara, L., Yeh, P., Martelotto, L. G., Rogiers, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10652-9 · Cited by 183
Self-citationCBP/p300 as a co-factor for the Microphthalmia transcription factor
Sato, S., Roberts, K., Gambino, G., Cook, A., Kouzarides, T., & Goding, C. R. (1997) · Oncogene · doi:10.1038/sj.onc.1201298 · Cited by 181
Self-citationMechanoresponsive stem cells acquire neural crest fate in jaw regeneration
Ransom, R. C., Carter, A. C., Salhotra, A., Leavitt, T., Marecic, O., Murphy, M. P., Lopez, M. L., Wei, Y., Marshall, C. D., Shen, E. Z., et al. (2018) · Nature · doi:10.1038/s41586-018-0650-9 · Cited by 178
Melanoma cell invasiveness is regulated by miR‐211 suppression of the BRN2 transcription factor
Boyle, G. M., Woods, S. L., Bonazzi, V. F., Stark, M. S., Hacker, E., Aoude, L. G., Dutton‐Regester, K., Cook, A. L., Sturm, R. A., & Hayward, N. K. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00849.x · Cited by 177
Giorgetti, L., Siggers, T., Tiana, G., Caprara, G., Notarbartolo, S., Corona, T., Pasparakis, M., Milani, P., Bulyk, M. L., & Natoli, G. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.016 · Cited by 175
A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Shi, H., Hong, A., Kong, X., Koya, R. C., Song, C., Moriceau, G., Hugo, W., Yu, C. C., Ng, C., Chodon, T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0279 · Cited by 173
Hughes, A. E., Newton, V. E., Liu, X. Z., & Read, A. P. (1994) · Nature Genetics · doi:10.1038/ng0894-509 · Cited by 171
A stress-induced early innate response causes multidrug tolerance in melanoma
Ravindran Menon, D., Das, S., Krepler, C., Vultur, A., Rinner, B., Schauer, S., Kashofer, K., Wagner, K., Zhang, G., Bonyadi Rad, E., et al. (2015) · Oncogene · doi:10.1038/onc.2014.372 · Cited by 170
Verastegui, C., Bille, K., Ortonne, J.-P., & Ballotti, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000445200 · Cited by 170
Targeting minimal residual disease: a path to cure?
Luskin, M. R., Murakami, M. A., Manalis, S. R., & Weinstock, D. M. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.125 · Cited by 168
Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming
García‐Jiménez, C., & Goding, C. R. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.11.018 · Cited by 168
Self-citationLee, M., Goodall, J., Verastegui, C., Ballotti, R., & Goding, C. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003816200 · Cited by 165
Self-citationIonizing Radiation Induces Stemness in Cancer Cells
Ghisolfi, L., Keates, A. C., Hu, X., Lee, D.-K., & Li, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043628 · Cited by 165
Chisholm, R. H., Lorenzi, T., Lorz, A., Larsen, A. K., de Almeida, L. N., Escargueil, A. E., & Clairambault, J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2103 · Cited by 164
Cisplatin Induces Bmi-1 and Enhances the Stem Cell Fraction in Head and Neck Cancer
Nör, C., Zhang, Z., Warner, K. A., Bernardi, L., Visioli, F., Helman, J. I., Roesler, R., & Nor, J. E. (2014) · Neoplasia · doi:10.1593/neo.131744 · Cited by 164
Kubic, J. D., Young, K. P., Plummer, R. S., Ludvik, A. E., & Lang, D. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00514.x · Cited by 160
Overview of Cancer Stem Cells and Stemness for Community Oncologists
Lathia, J. D., & Liu, H. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0508-3 · Cited by 154
Directed Phenotype Switching as an Effective Antimelanoma Strategy
Sáez‐Ayala, M., Montenegro, M. F., Sánchez‐del‐Campo, L., Fernández-Pérez, M. P., Chazarra, S., Freter, R., Middleton, M. R., Piñero, A., Cabezas‐Herrera, J., Goding, C. R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.009 · Cited by 147
Self-citationTargeting mitochondria in cancer: current concepts and immunotherapy approaches
Pustylnikov, S., Costabile, F., Beghi, S., & Facciabene, A. (2018) · Translational research · doi:10.1016/j.trsl.2018.07.013 · Cited by 144
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
Spagnolo, F., Ghiorzo, P., & Queirolo, P. (2014) · Oncotarget · doi:10.18632/oncotarget.2602 · Cited by 139
Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH
Torre, E. A., Dueck, H., Shaffer, S. M., Gospočić, J., Gupte, R. K., Bonasio, R., Kim, J., Murray, J. I., & Raj, A. (2018) · Cell Systems · doi:10.1016/j.cels.2018.01.014 · Cited by 138
Giuliano, S., Cheli, Y., Ohanna, M., Bonet, C., Beuret, L., Bille, K., Loubat, A., Hofman, V., Hofman, P., Ponzio, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2913 · Cited by 135
Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF
Feige, E., Yokoyama, S., Levy, C., Khaled, M., Igras, V., Lin, R. J., Lee, S., Widlund, H. R., Granter, S. R., Kung, A. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106351108 · Cited by 134
Yavuzer, U., Keenan, E., Lowings, P., Vachtenheim, J., Currie, G., & Goding, C. R. (1995) · PubMed · Cited by 128
Self-citationReal‐time cell cycle imaging during melanoma growth, invasion, and drug response
Haass, N. K., Beaumont, K. A., Hill, D. S., Anfosso, A., Mrass, P., Munoz, M. A., Kinjyo, I., & Weninger, W. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12274 · Cited by 127
Köhler, C., Nittner, D., Rambow, F., Radaelli, E., Stanchi, F., Vandamme, N., Baggiolini, A., Sommer, L., Berx, G., van den Oord, J. J., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.08.003 · Cited by 126
Self-citationCharacterization of Melanoma Cells Capable of Propagating Tumors from a Single Cell
Held, M. A., Curley, D. P., Dankort, D. L., McMahon, M., Muthusamy, V., & Bosenberg, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2153 · Cited by 123
MITF has a central role in regulating starvation-induced autophagy in melanoma
Möller, K., Sigurbjörnsdóttir, S., Arnthorsson, A. O., Pogenberg, V., Dilshat, R., Fock, V., Brynjólfsdóttir, S. H., Bindesbøll, C., Bessadóttir, M., Ogmundsdottir, H. M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37522-6 · Cited by 123
Thurber, A. E., Douglas, G., Sturm, E. C., Zabierowski, S. E., Smit, D. J., Ramakrishnan, S. N., Hacker, E., Leonard, J. H., Herlyn, M., & Sturm, R. A. (2011) · Oncogene · doi:10.1038/onc.2011.33 · Cited by 118
Focus on cutaneous and uveal melanoma specificities
Pandiani, C., Béranger, G. E., Leclerc, J., Ballotti, R., & Bertolotto, C. (2017) · Genes & Development · doi:10.1101/gad.296962.117 · Cited by 118
Bai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107 · cited 2×
“In a recent review (Bai et al. 2019), it has been proposed that the majority of cells within a melanoma tumor will exist in a continuous spectrum of states rather than fit any specific category and that the outliers will be the most unstable and therefore more likely to revert back to the most common state shared by t…”
BackgroundLister, J. A., Capper, A., Zeng, Z., Mathers, M. E., Richardson, J., Paranthaman, K., Jackson, I. J., & Patton, E. E. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.293 · Cited by 107
Intratumoral Heterogeneity as a Therapy Resistance Mechanism
Somasundaram, R., Villanueva, J., & Herlyn, M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00011-7 · Cited by 106
de la Serna, I. L., Ohkawa, Y., Higashi, C., Dutta, C., Osias, J., Kommajosyula, N., Tachibana, T., & Imbalzano, A. N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512052200 · Cited by 106
Single-cell gene expression signatures reveal melanoma cell heterogeneity
Ennen, M., Keime, C., Kobi, D., Mengus, G., Lipsker, D. M., Thibault-Carpentier, C., & Davidson, I. (2014) · Oncogene · doi:10.1038/onc.2014.262 · Cited by 100
Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
Yin, C., Zhu, B., Zhang, T., Liu, T., Chen, S., Liu, Y., Li, X., Miao, X., Li, S., Mi, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.002 · Cited by 100
Self-citationBiological and mathematical modeling of melanocyte development
Luciani, F., Champeval, D., Herbette, A., Denat, L., Aylaj, B., Martinozzi, S., Ballotti, R., Kemler, R., Goding, C. R., VUYST, F. D., et al. (2011) · Development · doi:10.1242/dev.067447 · Cited by 99
Self-citationBRAF/MAPK and GSK3 signaling converges to control MITF nuclear export
Ngeow, K. C., Friedrichsen, H. J., Li, L., Zeng, Z., Andrews, S., Volpon, L., Brunsdon, H., Berridge, G., Picaud, S., Fischer, R., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810498115 · Cited by 99
Self-citationTranscriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration
Wang, Z., Cao, S., Morris, J. S., Ahn, J., Liu, R., Tyekucheva, S., Gao, F., Li, B., Lü, W., Tang, X., et al. (2018) · iScience · doi:10.1016/j.isci.2018.10.028 · Cited by 96
Zhang, T., Zhou, Q., Ogmundsdottir, M. H., Möller, K., Siddaway, R., Larue, L., Hsing, M., Kong, S. W., Goding, C. R., Pálsson, A., et al. (2015) · Journal of Cell Science · doi:10.1242/jcs.173807 · Cited by 95
Self-citationJavelaud, D., Alexaki, V. I., Pierrat, M., Hoek, K. S., Dennler, S., van Kempen, L. C. L. T., Bertolotto, C., Ballotti, R., Saule, S., Delmas, V., et al. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00893.x · Cited by 93
Cited by
The plasticity of mRNA translation during cancer progression and therapy resistance
Fabbri, L., Chakraborty, A., Robert, C., & Vagner, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00380-y · Cited by 276
Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma
Wouters, J., Kalender-Atak, Z., Minnoye, L., Spanier, K. I., De Waegeneer, M., Bravo González-Blas, C., Mauduit, D., Davie, K., Hulselmans, G., Najem, A., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0547-3 · Cited by 258
Self-citationA TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma
Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.037 · Cited by 199
Self-citationBRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
Cross-species analysis of enhancer logic using deep learning
Minnoye, L., Taskiran, I. I., Mauduit, D., Fazio, M., Van Aerschot, L., Hulselmans, G., Christiaens, V., Makhzami, S., Seltenhammer, M., Karras, P., et al. (2020) · Genome Research · doi:10.1101/gr.260844.120 · Cited by 116
Self-citation
Metadata
- Authors
- Rambow, F., Marine, J.-C., & Goding, C. R.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2019-10-01
- Volume
- 33
- Issue
- 19-20
- Pages
- 1295-1318
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2978972173
- Cited by
- 325
- References
- 227
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.